AlloVir Inc (ALVR)
0.7766
+0.03
(+3.35%)
USD |
NASDAQ |
May 17, 16:00
0.7766
0.00 (0.00%)
After-Hours: 20:00
AlloVir Enterprise Value: -51.36M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -51.36M |
| May 16, 2024 | -54.12M |
| May 15, 2024 | -54.28M |
| May 14, 2024 | -51.74M |
| May 13, 2024 | -54.27M |
| May 10, 2024 | -50.19M |
| May 09, 2024 | -46.64M |
| May 08, 2024 | -50.62M |
| May 07, 2024 | -48.95M |
| May 06, 2024 | -47.79M |
| May 03, 2024 | -48.83M |
| May 02, 2024 | -47.85M |
| May 01, 2024 | -47.45M |
| April 30, 2024 | -49.24M |
| April 29, 2024 | -46.93M |
| April 26, 2024 | -48.93M |
| April 25, 2024 | -48.60M |
| April 24, 2024 | -50.90M |
| April 23, 2024 | -49.65M |
| April 22, 2024 | -52.85M |
| April 19, 2024 | -54.32M |
| April 18, 2024 | -55.25M |
| April 17, 2024 | -53.55M |
| April 16, 2024 | -56.08M |
| April 15, 2024 | -54.79M |
| Date | Value |
|---|---|
| April 12, 2024 | -52.43M |
| April 11, 2024 | -51.80M |
| April 10, 2024 | -54.28M |
| April 09, 2024 | -55.07M |
| April 08, 2024 | -55.89M |
| April 05, 2024 | -54.72M |
| April 04, 2024 | -53.24M |
| April 03, 2024 | -52.35M |
| April 02, 2024 | -52.36M |
| April 01, 2024 | -48.07M |
| March 28, 2024 | -97.23M |
| March 27, 2024 | -96.47M |
| March 26, 2024 | -97.79M |
| March 25, 2024 | -96.60M |
| March 22, 2024 | -97.50M |
| March 21, 2024 | -95.39M |
| March 20, 2024 | -98.33M |
| March 19, 2024 | -98.25M |
| March 18, 2024 | -99.87M |
| March 15, 2024 | -94.47M |
| March 14, 2024 | -100.47M |
| March 13, 2024 | -100.27M |
| March 12, 2024 | -98.94M |
| March 11, 2024 | -100.72M |
| March 08, 2024 | -100.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-135.78M
Minimum
Dec 29 2023
2.508B
Maximum
Dec 04 2020
628.06M
Average
347.83M
Median
Feb 24 2022
Enterprise Value Benchmarks
| CEL-SCI Corp | 63.47M |
| AIM ImmunoTech Inc | 7.729M |
| IGC Pharma Inc | 34.45M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.30M |
| Total Expenses (Quarterly) | 22.84M |
| EPS Diluted (Quarterly) | -0.26 |
| Earnings Yield | -214.1% |